Article Details
Retrieved on: 2018-03-21 21:30:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div><b>Third Rock Ventures</b> unwrapped its latest biotech baby this morning. The new company—Rheos Medicines—is focused on the emerging field of immunometabolism and makes its debut with $60 million in first-round funding. Rheos' approach to immunometabolism is to try to identify metabolic pathways ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here